Stay updated on KD025 Efficacy and Safety in cGVHD Clinical Trial

Sign up to get notified when there's something new on the KD025 Efficacy and Safety in cGVHD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the KD025 Efficacy and Safety in cGVHD Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of subjects with active cGVHD who will be randomized to receive treatment with different regimens of belumosudil in a Phase 2 clinical study for Chronic Graft Versus Host Disease.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:04.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying that male and female subjects aged 12 and older who have had an allogenic hematopoietic cell transplant and meet certain health conditions are eligible. Previously, this section had no information provided.
    Difference
    11%
    Check dated 2024-05-22T20:20:49.000Z thumbnail image
  7. Check
    40 days ago
    Change Detected
    Summary
    The value 'Go to the classic website' has been updated to 'Site Map' on the webpage, indicating a change in the type of intervention being highlighted. This change may be related to medical and healthcare-related publications and documentation.
    Difference
    0.9%
    Check dated 2024-05-01T17:48:49.000Z thumbnail image

Stay in the know with updates to KD025 Efficacy and Safety in cGVHD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the KD025 Efficacy and Safety in cGVHD Clinical Trial page.